The APP Role in Advancing Anti-HER2 Treatment for Gastroesophageal Adenocarcinoma CME/CNE/CPE/IPCE Minneapolis Convention Center Thursday, October 15, 2026 9:30 am - 10:30 am CT

https://na.eventscloud.com/website/98965/ Novel anti-HER2 regimens with unique safety profiles are poised to expand treatment options for patients with gastroesophageal adenocarcinoma (GEA). Designed specifically for advanced practice professionals, this 60-minute live symposium explores where new agents fit into care for human epidermal growth factor receptor 2 (HER2)-positive GEA and best approaches for toxicity management.